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Abstract 36 
Depending on how the future will unfold, today’s progress in biotechnology research 37 
has greater or lesser potential to be the basis of subsequent innovation. Tracking 38 
progress against indicators for different future scenarios would enable to focus, 39 
emphasize or de-emphasize discovery research timely and to maximize the chance 40 
for successful innovation. The COVID-19 crisis exemplifies that scenario indicators 41 
can offer time advantage to decisions on biotechnology research and innovation 42 
(R&I) investments, as well as to strategy development to minimize the spread of this 43 
type of disease. Tracking indicators that are specific for contrasting learning 44 
scenarios allows getting insights early in time when uncertainties pan out in a 45 
particular way, and can help the biotechnology field with its lengthy innovation 46 
timelines, high costs and uncertain future markets to develop most effectively. In this 47 
paper, we show how learning scenarios with a 2050 time horizon enable to recognize 48 
the implications of political and societal developments on the innovation potential of 49 
ongoing biotechnological research. We furthermore propose a model to further 50 
increase open innovation between academia and the biotechnology value chain to 51 
help fundamental research explore discovery fields that have a greater chance to be 52 
of value for applied research. 53 
Developing scenarios for biotechnology in complex social systems 54 
Biological science is expanding its knowledge frontiers at an ever-accelerating pace. 55 
The progressing insights into biological processes offer a broadening array of options 56 
to develop incremental and differential innovations across the medical, agricultural 57 
and industrial biotechnology sectors. 58 
As timelines from understanding basic biological processes to the conception of an 59 
innovation and the development of a marketable product may range from ten to 60 
twenty-five years, a prime question for today’s biotechnology discovery research is 61 





To this end, we conducted in 2019 a first of its kind scenario analysis with a 2050 64 
time horizon to understand the option space of agricultural biotechnology 65 
(https://www.cropbooster-p.eu/). Forty-five trends and twenty-two uncertainties 66 
dealing with the entire agricultural socio-economic system were reviewed to map the 67 
range of directions the future may take and to narrow down how agricultural 68 
biotechnology could best future-proof food, nutrition and health security. Trends 69 
ranged from consumer and demographics, farming and technology to politics, 70 
economy and societal developments while identified uncertainties were clustered 71 
around three themes: (1) needs for adaptation, (2) priorities in the value chain, and 72 
(3) the role of science (Fig. 2).  73 
In order to identify towards which scenario today’s world is heading, relevant 74 
indicators need to be developed [1,2]. For this, the critical developments or events 75 
that will be necessary for a scenario to arise need to be named, put in a 76 
chronological order through narratives, and checked for their informative value. 77 
Learning scenarios are reusable, and the scope of the indicators identified will 78 
depend on the diversity of expertise within the team exploiting the learning scenarios 79 
(Fig 3). Obvious examples of indicators are the developments around the legislation 80 
related to gene editing in the Bio-innovation and REJECTech scenario, personal data 81 
protection regulations in My choice scenario, while for instance the evolution of water 82 
availability in a particular country can be an indicator for Food emergency, as well as 83 
for Bio-innovation or REJECTech.  84 
 85 
Steering focus in biotechnology discovery research with scenarios  86 
The way the world will evolve will depend on a myriad of developments. Examples 87 
are the transition to renewable energy and decentralized storage, the global policy 88 
approach to enable the use of new genomic technologies, patients embracing new 89 
treatments, society buying into preventive medicine or demanding transparency 90 
about food properties, dietary shifts, development of new high-tech materials, shifts 91 
in lifestyle, and progress in robotics and artificial intelligence. Following such 92 
developments and extrapolating their long-term impact on the way we live, may 93 




discovery research that would provide the starting basis for R&I addressing future 95 
needs. 96 
Biotechnology discovery research will undoubtedly be at the core of numerous 97 
innovations that will reach society by 2050. However, depending on how the future 98 
will unfold, today’s progress in biotechnology research has a greater or lesser 99 
potential to be the basis of subsequent innovation. In addition, the lack of a 100 
widespread open innovation culture between industry and academia increases the 101 
risk of missing out on innovation that trend-wise is likely to meet industry or 102 
consumer demand. 103 
For example, it is clear that the demand for climate change related biotechnology 104 
innovation will be high, and will be supported by policy makers [3, 4]. However, what 105 
the unmet needs will be for the different stakeholder groups is still unclear. Effects on 106 
cities, gardens, parks, lakes and crop fields linked to shifts and volatility in weather 107 
and the resulting new environmental conditions, including new pests and diseases, 108 
are not yet fully appreciated. Consequently, a translational step from innovation 109 
opportunity to required new knowledge is not obvious. Similarly, it is not clear how to 110 
incorporate innovation into products [5]. It may range from gene editing to novel 111 
knowledge-driven, societally accepted workflows that are not yet in place. The first 112 
activity, developing climate change knowhow, has a low risk of not being of 113 
relevance. The second, developing biotechnology innovation addressing climate 114 
change, is dependent on how policies develop across the globe, and therefore 115 
carries a higher risk [6]. For example, whereas it is conceivable in a “Bio-innovation” 116 
world that society may see a broad replacement of fossil-based synthetic materials 117 
by bio-based alternatives, such a development is less likely to occur in a 118 
“REJECTech” setting, as although the knowhow to do so would exist, the technical 119 
enablement would not be supported.   120 
Another example relates to the exploitation of the microbiome. As microbes impact 121 
most, if not all, complex ecological systems, exploitation of biological knowhow is 122 
expected to offer innovation options in a broad range of biotechnology fields and be 123 
at the core of new markets and business models. These may include medicine, 124 
healthcare, food systems, industrial and household processes and materials, 125 




biotechnology discovery research on microbiomes needs to reach a tipping point, so 127 
that R&I for smaller and bigger opportunities across sectors becomes viable [7]. This 128 
necessitates a major public effort to advance pre-competitive knowhow and an 129 
enablement to a level sufficient for sector adoption within a reasonable risk 130 
perspective on a return of investment. A flagship approach in e.g. medicine building 131 
on ongoing big data efforts, such as in the human ‘100K genomes project’ [8], may 132 
serve as a vehicle to reach, in a five-year time span, the desired state of enablement 133 
and allow smaller initiatives to build on this cost-effectively. However, an 134 
entrepreneurial ecosystem is critical for this to happen, implying that such 135 
developments are more likely to occur under a “Bio-innovation” scenario or even in 136 
a “Food emergency” scenario, once society starts prioritizing access to food and 137 
health. 138 
A third example refers to diet shifts toward alternative protein sources. Consumer 139 
choice is highly dependent on food properties such as taste, texture, palatability, 140 
color, convenience and price. Making alternative protein products competitive to 141 
meat would require, amongst other improvements, major advances in biological 142 
insights to upgrade food sources [9]. The challenge is to get specific on the carriers, 143 
e.g. algae, insects, crops, fermentation, etc., and the exact properties, so that the 144 
investments in biotechnology discovery have an effect. To do this successfully is not 145 
obvious as it is currently not clear which products and product properties will match 146 
future market demands. This brings us back to the importance of contrasting learning 147 
scenarios and the need to identify scenario-specific indicators to get insights early in 148 
time about how particular trends are panning out. These indicators may relate to e.g. 149 
yes/no decision points in policy development, or the timely establishment of critical 150 
enabling technologies or of sizeable consumer demands. Tracking progress of 151 
multiple (scenario-specific) indicators thus helps to steer focus in discovery research 152 
and o emphasize or de-emphasize timely to maximize the chance for successful 153 
innovation.  154 
A current real-life example is the COVID-19 pandemic, an occurrence that was not 155 
foreseen because of which only relatively small and scattered efforts of research 156 
have been conducted prior to the pandemic. The current R&I race to develop a cure 157 
and vaccine against COVID-19 would have greatly benefitted from an advanced 158 




[10, 11]. Of course, in hindsight it is easy to highlight what should have been done. In 160 
practice, there are several million viruses in the world, over 200 of which are known 161 
to infect humans. Conducting extensive research on all these viruses in parallel 162 
would be too labor-intensive and unsustainable from an economical point of view. 163 
However, the current crisis reveals the advantage in time the use of scenario 164 
indicators can offer to international and local organizations dealing with public health. 165 
Such indicators might have flagged previous smaller outbreaks of other 166 
coronaviruses such as SARS (severe acute respiratory syndrome) and MERS 167 
(Middle East respiratory syndrome) in the last two decades. These outbreaks could 168 
then have been predictive for scenarios in which coronaviruses would become a 169 
major threat to human health, and could have triggered dedicated funding to advance 170 
specific biotechnological knowhow, as well as to develop strategies to minimize the 171 
spread of this type of disease. Major funding is currently being gathered to mitigate 172 
the consequences of the COVID-19 crisis, including $8 billion pledged by world 173 
leaders to support dedicated R&I [12]. However, today’s continuing need to conduct 174 
significant biotechnology discovery research means that time, not necessarily funding 175 
per se, is a bottleneck. Along the same lines, developing scenarios today to 176 
understand how the future may unfold in the context of the COVID-19 pandemic, 177 
could help anticipate the long-term consequences of the actions that are being taken 178 
and could allow countries, states and communities to react to the crisis more 179 
effectively. In the context of the scenarios presented in Figure 3, the current 180 
pandemic emerges as a relevant indicator for the Food emergency scenario. A 181 
global economic crisis may put critical agricultural supply chains at risk, such that 182 
food security becomes an even greater issue in certain world regions.  183 
 184 
Concluding Remarks 185 
The above biotechnology examples demonstrate the risk of a low innovation output 186 
when the founding knowhow obtained from discovery research is not readily 187 
available and accessible in a useable format.  The timely availability of founding 188 
knowhow may greatly improve by adopting the use of learning scenarios and the 189 
tracking of progress against indicators for these scenarios. To make such an 190 
approach effective, several outstanding issues need to be addressed first 191 





We strongly believe that to improve the innovation output, the discussion should go 194 
beyond “financial instruments” and “creativity”. Rather, we would recommend to look 195 
at how the innovation ecosystem functions [13]: To maximize the utilization of 196 
advances in knowhow, the current working principles between academia, value chain 197 
players and society would benefit from extensive review. Biological science needs a 198 
continuous cross-stakeholder interaction to move more efficiently from discovery to 199 
innovation. To steer biotechnological R&I more efficiently, an open innovation 200 
governance concept to deal with pre-competitive and competitive big data 201 
information and activities is an absolute pre-requisite 202 
We therefore propose to install virtual innovation workflows spanning academia and 203 
value chain players to address societal demands (Fig. 4). The idea is to set up 204 
dedicated ecosystem knowledge bases that serve, for example, the medical, 205 
agricultural or industrial biotechnology sectors or serve a broad innovation field such 206 
as the microbiome. These ecosystem knowledge bases should harbor harmonized 207 
and curated data in formats tailored to stakeholder use requirements. Such 208 
requirements can be defined for each of the biotechnology fields in a two-step 209 
process. First the generic workflow at handover points between academia and value 210 
chain players should be described, followed by the data and format requirements in 211 
this generic workflow, which would be necessary to start. These processes should 212 
ideally be described in both directions. In addition, users extracting information with 213 
their own software, if private, should commit to upload outcomes that are made 214 
anonymous, so that the next round of experimental questions can consider advanced 215 
information, and the knowledge base increases over time both in scope and in 216 
predictiveness.  217 
 218 
To make this workable and sustainable, appropriate business models and 219 
governance concepts to deal with, among others, data ownership and intellectual 220 
property need to be developed, and dedicated data stewardship teams need to be 221 
installed. Setting this up will likely need several rounds of optimization to reach the 222 




the overall flow of innovation to the market and to offer the desired flexibility to deal 224 
with upcoming trends in an ever-changing world. 225 
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Figure 1. Innovation flow. In the coming 15 years, the market will be served by R&D 234 
that is performed today. Different biotechnology sectors address changes in demand 235 
by repositioning and emphasizing what is in today’s pipeline. New R&D and public 236 
research ideally address the demand of the future market. Scenario analysis is well 237 
suited to narrow down the most promising fields of investigation and to address the 238 
unmet needs of future markets. R: research; D: development.   239 
Figure 2. Trends and uncertainties. Trends are considered developments going in 240 
a certain direction, while uncertainties can determine distinct outcomes with very 241 
different implications. Here the two most extreme ways that the uncertainties could 242 
play out are presented. Examples of specific uncertainties clustered around three 243 
more general themes are provided in the footnote. 244 
The exercise delivered four contrasting learning scenarios by detailing out specific 245 
aspects of possible future worlds and making them as concrete and vivid as possible. 246 
(Fig. 3). As the selected trends and uncertainties deal with society, environment, 247 
innovation and policy, the learning scenarios helped to characterize implications not 248 
only for the future of agriculture in Europe, which was the initial scope of the scenario 249 
building, but they can also serve to aid decisions on future research and innovation 250 
(R&I) investments in other fields of biotechnology globally.  251 
Figure 3. Learning scenarios. Four contrasting learning scenarios enable us to 252 
delineate the option space for the direction and context of future biotechnology. Bio-253 




sufficient high-quality food and large volume feedstock for a thriving bioeconomy; My 255 
choice: Health and sustainability concerns drive all sectors to be diverse and 256 
transparent, meeting the needs and preferences of individuals, personalized 257 
medicine and nutrition are the norm; REJECTech: Consumers have little trust in 258 
politicians, scientists and big industry. Society is highly polarized and rejects 259 
biotechnology-derived products and services, despite dissatisfaction about missed 260 
opportunities, such as a broad adoption of the bioeconomy due to limited agricultural 261 
production; Food emergency: Due to severe environmental degradation, the world is 262 
struggling to fulfill basic food demand. In response to the crisis, global adoption of 263 
innovation, including biotechnology, occurs to mitigate impacts.  264 
Figure 4. Outline of a future “virtual innovation workflow” driven by 265 
biotechnology big data governance. An example is given for agricultural innovation 266 
in Europe. To meaningfully contribute to the EU Green Deal, a rejuvenation of the 267 
agricultural ecosystem including academia, breeding and R&D companies, farm 268 
supply industry and farmers, is desirable. Required innovations should address 269 
environmental sustainability, impacts of increased weather volatility, climate change 270 
and associated pest and disease development, the European protein plan, 271 
development of more healthy and nutritious food, and an enablement of the bio-272 
economy. It should offer a lever to improve farm economics structurally through 273 
product branding and traceability. The novelty of the proposed “virtual innovation 274 
workflow” is the bidirectional handover of outcomes and the holistic integration of 275 
data coming from plant, microbial, soil, agronomy, robotization, machine learning, 276 
modelling and weather/climate disciplines. Critical success factors are, amongst 277 
others, the alignment of key performance indicators of stakeholders, incentives to 278 
participate, an open innovation attitude, a common benchmark to measure progress, 279 
smartly located research field stations, dedicated data centers with a user-oriented 280 
data curation, harmonization, storage and display approach, and an agreeable data 281 
governance concept. A pipeline of consecutive innovations can be primed by raising, 282 
over time, the requirements to pass successfully the formal variety testing and 283 
registration process. Customer demand (not shown) is in this example translated to 284 
requirements for official variety testing trials that e.g. meet progressively increasing 285 
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Outstanding Questions 
1. How to motivate all relevant stakeholders to develop jointly a common understanding of 
learning scenarios and their impact?   
2. How to ensure that scenarios are timely updated to address specific developments over time, 
including aspects that were not covered during earlier scenario exercises? 
3. How to organise the tracking of indicators and the dissemination of weaker and stronger signals 
that may indicate direction of change before any of the scenarios fully materializes? 
4. How to improve the quality of scenario development and its utilization by the latest 












2) AI & Big Data
3) Altered Genetic Resources Circulation








12) Cultivar / Species Mixtures
13) Decline of Pollinators & Biodiversity
14) Declining Chemistry for Pest Control
15) Diet-related Chronic Diseases
16) Do-it-Yourself
17) E-Commerce










28) NBTs & Genetic Modification
29) Offering of Meat Alternatives
30) Organic Farming
31) Plant Beneficial Microbes
32) Population Growth
33) Power of the Online Public
34) Product & Research Regulation
35) Public Engagement in Research
36) Renewable Energy
37) Resource Scarcity
38) Rising Disposable Income
39) Risk Sensitivity
40) Robotics
41) Self-Tracking / Quantified Self
42) Sustainability
43) Transparency







Strong demand for nonfood
Ban of wide range of biotech
Failures and abandonment
Very low
Impact of environmental changes1
Development of demography2
Development of the economy3
Development of the political environment
Importance of sustainability4
Role of the bioeconomy: food vs. non-food
Development of advanced biotech
Development of non-biological tech5




Collaborative, open markets 
Not important
Focus on food 










4 e.g., environmental concerns, animal welfare, organic farming,…
5 e.g., robots, AI, VR/AR, blockchain,…
1 e.g., climate change, resources scarcity, development of pests, loss in biodiversity,…
2 e.g., size of population, age, chronic diseases,...
3 e.g., prices, income, equality,…
Figure 2
Figure 3
Figure 4
